Detail akcie iCAD online

Business Summary: iCAD, Inc. provides artificial intelligence-powered cancer detection. Its ProFound Breast Health Suite enables medical providers and professionals to accurately and reliably identify where cancer may be hiding. Its Cancer Detection segment solutions include advanced artificial intelligence and image analysis workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing the prevalent cancers earlier, a range of upgradeable computer-aided detection systems and workflow solutions for digital breast tomosynthesis, full-field digital mammography, magnetic resonance imaging and computed tomography. ProFound Suite offers 360-degree solutions for cancer detection, density assessment, and personalized risk evaluation, all based on a 2D or 3D mammogram’s collection of images. ProFound Density Assessment standardizes and simplifies breast density reporting, algorithmically examining a woman’s breast anatomy from the mammogram image.
Financial Summary: BRIEF: For the three months ended 31 March 2024, iCAD Inc revenues increased 14% to $5M. Net loss before extraordinary items decreased 60% to $1.2M. Revenues reflect Products increase of 26% to $3.1M. Lower net loss reflects General and administrative - Balancing v decrease of 29% to $1.8M (expense), Stock-based Compensation in SGA decrease of 62% to $146K (expense), Marketing and sales - Balancing value decrease of 9% to $2M (expense).